Louise R. Howe
- Pharmacology top 0.5%
- Inflammatory mediators and NSAID effects 18
- Cancer Research top 2%
- Cancer, Lipids, and Metabolism 4
- Oncology top 2%
- Cancer Risks and Factors 3
- Molecular Biology top 5%
- Wnt/β-catenin signaling in development and cancer 7
- Cancer-related gene regulation 5
- Protein Kinase Regulation and GTPase Signaling 4
- Genetics top 2%
- Estrogen and related hormone effects 16
-
- Cancer, Stress, Anesthesia, and Immune Response 7
- Co-authors
- Andrew J. DannenbergAnthony M.C. BrownKotha SubbaramaiahChristopher J. MarshallSally J. LeeversNéstor GómezPhilip CohenSara Nakielny
- Cited by
- PharmacologyCancer ResearchOncology
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Louise R. Howe
37 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 117
- Pharmacology 1.1k
- Cancer Research 702
- Oncology 1.1k
- Molecular Biology 2.5k
- Genetics 959
Countries citing papers authored by Louise R. Howe
This map shows the geographic impact of Louise R. Howe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise R. Howe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise R. Howe more than expected).
Fields of papers citing papers by Louise R. Howe
This network shows the impact of papers produced by Louise R. Howe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise R. Howe. The network helps show where Louise R. Howe may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Louise R. Howe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 37 | |
| 2 | 2015 | 162 | |
| 3 | 2013 | 25 | |
| 4 | 2012 | 41 | |
| 5 | 2012 | 96 | |
| 6 | 2010 | 18 | |
| 7 | 2007 | 243 | |
| 8 | 2005 | 114 | |
| 9 | 2004 | 49 | |
| 10 | 2004 | 87 | |
| 11 | 2004 | 272 | |
| 12 | 2003 | 40 | |
| 13 | Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. | 2002 | 177 |
| 14 | 2002 | 57 | |
| 15 | 2001 | 112 | |
| 16 | 2001 | 409 | |
| 17 | 2001 | 274 | |
| 18 | 1995 | 83 | |
| 19 | 1993 | 138 | |
| 20 | Activation of the MAP kinase pathway by the protein kinase rafbreakdown → | 1992 | 727 |
About Louise R. Howe
Louise R. Howe is a scholar working on Pharmacology, Genetics and Psychiatry and Mental health, having authored 37 papers that have together received 4.4k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (18 papers), Estrogen and related hormone effects (16 papers), Cancer, Stress, Anesthesia, and Immune Response (7 papers), Wnt/β-catenin signaling in development and cancer (7 papers), Cancer-related gene regulation (5 papers), Cancer, Lipids, and Metabolism (4 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and Cancer Risks and Factors (3 papers). The work is most often cited by research in Pharmacology (1.1k citations), Cancer Research (702 citations) and Oncology (1.1k citations). Louise R. Howe has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Andrew J. Dannenberg, Anthony M.C. Brown, Kotha Subbaramaiah, Christopher J. Marshall, Sally J. Leevers, Néstor Gómez, Philip Cohen, Sara Nakielny, C. J. Marshall and Clifford A. Hudis. Their work appears in journals such as Cell, Journal of Biological Chemistry and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.